DENTSPLY SIRONA Inc.
- Open
- 10.61
- Day high
- 11.10
- Day low
- 10.61
- Prev close
- 10.61
- Volume
- 2.6M
- Mkt cap
- $2.2B
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 1.7
- P/S
- 0.6
- Yield
- —
- Per share
- —
- ▲Insiders net buying $617K over the last 3 months (6 open-market buys, 0 sales)
- ◆Cluster buying — multiple insiders bought within days
- 🏛Institutions mixed (13F)
DENTSPLY SIRONA Inc. (XRAY) is a Healthcare company listed on NASDAQ. The stock is down 36% over the past year. Over the trailing 3 months, insiders filed 6 open-market buys and 0 sales (SEC Form 4).
DENTSPLY SIRONA Inc. (XRAY) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 4 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
XRAY earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 5, 2026 | $0.28 | $0.27 | -3.6% | $880M | +4.5% |
| Nov 6, 2025 | $0.45 | $0.37 | -17.8% | $904M | -2.5% |
| Aug 7, 2025 | $0.50 | $0.52 | +4.0% | $936M | +3.5% |
| May 8, 2025 | $0.29 | $0.43 | +48.3% | $879M | -4.5% |
| Feb 27, 2025 | $0.47 | $0.26 | -44.7% | $905M | +0.4% |
| Nov 7, 2024 | $0.48 | $0.50 | +4.2% | $951M | +1.5% |
| Jul 31, 2024 | $0.50 | $0.49 | -2.0% | $984M | -1.2% |
| May 2, 2024 | $0.42 | $0.42 | +0.0% | $953M | -1.7% |
| Feb 29, 2024 | $0.43 | $0.44 | +2.3% | $1.0B | +3.6% |
| Nov 2, 2023 | $0.48 | $0.49 | +2.1% | $947M | -2.9% |
| Aug 2, 2023 | $0.43 | $0.51 | +18.6% | $1.0B | +5.7% |
| Nov 14, 2022 | $0.59 | $0.41 | -30.5% | $947M | -6.0% |
XRAY insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jun 18, 2026 | MAZELSKY JONATHAN JAYdirector | Buy | 10,000 | $10.14 |
| Jun 16, 2026 | HOSEIN CLYDEdirector | Buy | 6,500 | $9.98 |
| Jun 15, 2026 | Barber Michael Jdirector | Buy | 15,175 | $9.88 |
| Jun 15, 2026 | HOLDEN BETSY Ddirector | Buy | 10,086 | $9.88 |
| Jun 15, 2026 | MCKEON BRIAN Pdirector | Buy | 10,000 | $10.12 |
| Jun 15, 2026 | Gladden Brian Tdirector | Buy | 9,985 | $10.02 |
| Jun 15, 2026 | MAZELSKY JONATHAN JAYdirector | Grant | 10,000 | $10.14 |
| Jun 5, 2026 | LUCIER GREGORY Tdirector | Grant | 38,382 | — |
| Jun 5, 2026 | Forbes James Ddirector | Grant | 28,887 | — |
| Jun 5, 2026 | MCKEON BRIAN Pdirector | Grant | 28,887 | — |
| Jun 5, 2026 | VARON LESLIE Fdirector | Grant | 22,822 | — |
| Jun 5, 2026 | LUCIER GREGORY Tdirector | Grant | 10,900 | $9.64 |
| Jun 5, 2026 | Vergis Janet S.director | Grant | 22,822 | — |
| Jun 5, 2026 | HOLDEN BETSY Ddirector | Grant | 22,822 | — |
| Jun 5, 2026 | Barber Michael Jdirector | Grant | 22,822 | — |
Source: XRAY SEC Form 4 filings, latest Jun 18, 2026. For informational purposes only — not investment advice.
See the full XRAY insider & 13F page →DENTSPLY SIRONA Inc. company profile
Overview
DENTSPLY SIRONA Inc. (NASDAQ:XRAY) is a leading global manufacturer and distributor of dental products and technologies, serving the professional dental market worldwide. Founded in 1877 and publicly traded since 1987, the company was formed through the 2016 merger of DENTSPLY International and Sirona Dental Systems. Headquartered in Charlotte, North Carolina, DENTSPLY SIRONA has evolved from a traditional dental supply company into a comprehensive provider of digital dental solutions, equipment, and consumables for dental professionals and specialists globally.
Business
DENTSPLY SIRONA operates in the global dental industry, providing a comprehensive portfolio of products and services to dental professionals, specialists, and laboratories. The company's offerings span the entire dental workflow, from diagnostic equipment to treatment tools and consumable materials. The company operates through four main business segments: Essential Dental Solutions (EDS) represents the largest revenue segment, encompassing traditional dental consumables and materials. This includes endodontic products such as drills, files, sealers, and irrigation tools used in root canal procedures; restorative products including artificial teeth, dental ceramics, precious metal alloys, and crown and bridge materials; and preventive care products like dental anesthetics, prophylaxis paste, dental sealants, impression materials, and teeth whiteners. This segment generates approximately 40-45% of total revenue. Connected Technology Solutions (CTS) focuses on digital dental equipment and technologies. Key products include dental treatment centers, imaging equipment, motorized handpieces, and the company's flagship CAD/CAM (Computer-Aided Design/Computer-Aided Manufacturing) systems that enable dental offices to design and manufacture dental restorations digitally. The segment also includes the DS Core digital platform, which connects various dental devices and workflows. This segment accounts for roughly 30-35% of revenue. Orthodontic and Implant Solutions comprises two major product categories: clear aligner systems including the SureSmile professional platform and the direct-to-consumer Byte brand (though Byte operations were suspended in 2024), and dental implant systems for tooth replacement procedures. This segment represents approximately 15-20% of total revenue. Wellspect Healthcare is a specialized medical device business focused on urology and continence care products, including catheters and other healthcare consumables. This non-dental segment contributes about 5-10% of total revenue and is currently under strategic review for potential divestiture.
Revenue model
DENTSPLY SIRONA generates revenue through multiple business models across its diverse product portfolio. The company primarily operates on a product sales model, selling both durable equipment and consumable products to dental professionals, laboratories, and distributors worldwide. The Equipment Sales model involves selling high-value capital equipment such as dental treatment centers, imaging systems, and CAD/CAM machines to dental practices. These sales typically involve higher margins but longer sales cycles and are more sensitive to macroeconomic conditions affecting dental practice capital expenditure decisions. The Consumables Model provides recurring revenue through the sale of disposable and replaceable dental materials, tools, and supplies that dental practices use regularly. This includes items like endodontic files, impression materials, dental ceramics, and preventive care products. This model offers more predictable revenue streams with shorter replenishment cycles. The Digital Platform and Software revenue comes from the DS Core ecosystem, which connects dental devices and provides workflow management solutions. While currently a smaller revenue contributor, this represents a growing subscription and service-based revenue stream. The Clear Aligner Business operates through both professional (SureSmile) and direct-to-consumer (Byte, now suspended) channels, with revenue generated through treatment case sales and ongoing monitoring services. Several factors significantly impact the company's margins and profitability. Positive margin drivers include the company's ongoing digital transformation initiatives, which command premium pricing; successful product innovation and new launches; operational efficiency improvements from manufacturing consolidation and ERP system implementations; and the shift toward higher-margin digital and software-based solutions. Negative margin pressures come from intense competition in traditional dental markets leading to pricing pressure; macroeconomic headwinds affecting dental practice capital spending; supply chain disruptions and raw material cost inflation; regulatory challenges, particularly in the direct-to-consumer aligner market; and significant restructuring and transformation costs as the company modernizes its operations and technology infrastructure.
Competitive moat
DENTSPLY SIRONA's competitive moat is moderate but facing erosion in several key areas. The company's traditional strengths lie in its comprehensive product portfolio and established relationships with dental professionals built over nearly 150 years of operation. The company benefits from significant scale advantages as one of the largest dental supply companies globally, providing leverage in procurement, manufacturing, and distribution. The company's most promising moat development is its DS Core digital ecosystem, which aims to create switching costs by integrating various dental devices and workflows into a unified platform. With over 42,000 users and 50,000 connected devices, this platform has the potential to create meaningful customer stickiness, though it's still in relatively early adoption stages compared to the total addressable market. However, the company faces significant competitive pressures that limit its moat strength. In the equipment segment, DENTSPLY SIRONA competes against well-funded rivals like Align Technology in orthodontics, Straumann and Nobel Biocare in implants, and various regional players in CAD/CAM systems. The digital transformation of dentistry has lowered barriers to entry for software-focused competitors who can offer more specialized solutions. The consumables business, while providing recurring revenue, faces commoditization pressures as many products become standardized. Generic and private-label alternatives increasingly compete on price, particularly in basic consumable categories. The company's clear aligner business faces intense competition from market leader Align Technology (Invisalign) and numerous emerging competitors. The suspension of Byte operations highlights execution challenges in this critical growth market. Overall, while DENTSPLY SIRONA maintains market leadership in several categories, its moat is primarily defensive rather than offensive, relying more on scale and relationships than on truly differentiated technology or insurmountable competitive advantages. The success of the DS Core platform and digital transformation initiatives will be crucial for strengthening the company's long-term competitive position.
Risks & safety
The company presents moderate financial risk with some concerning liquidity and profitability metrics, though recent operational improvements provide some stability. **Liquidity and Solvency:** - Current ratio of 1.10 indicates tight working capital management - Quick ratio of 0.76 suggests potential short-term liquidity constraints - Cash position of $398 million provides reasonable cushion - Free cash flow turned negative at -$12 million in Q1 2025, though this improved from prior quarters - Debt-to-equity ratio of 1.21 indicates elevated leverage levels **Profitability Concerns:** - Company reported significant losses in 2024 with negative EBITDA of -$532 million for the full year - Recent quarters show improvement with positive EBITDA of $63 million in Q1 2025 - Return on equity remains very low at 1.0% **Valuation Metrics:** - Trading at 37.2x P/E ratio based on recent positive earnings, though this reflects recovery from losses - EV/EBITDA of 19.8x appears reasonable given the turnaround situation - Price-to-book ratio of 1.48x suggests modest valuation relative to book value **Other Considerations:** - Ongoing restructuring costs and transformation investments create near-term earnings volatility - Wellspect divestiture process could provide additional cash resources - Tariff exposure of approximately $0.10 per share creates external risk factors
Recent development
Over the past few years, DENTSPLY SIRONA has undergone significant strategic transformation aimed at digitizing its business model and improving operational efficiency. The company has implemented a comprehensive Phase II restructuring program targeting $80-100 million in annual cost savings through workforce reduction, manufacturing consolidation, and supply chain optimization. A major strategic pivot has been the company's focus on digital connectivity through its DS Core platform, which has grown to over 42,000 users and 50,000 connected devices. This ecosystem integrates various dental equipment and software solutions to create a unified digital workflow for dental practices. The company has also invested heavily in ERP system modernization and completed its largest individual ERP deployment phase in the U.S. In the orthodontics segment, the company made the significant decision to suspend Byte operations in 2024 due to regulatory challenges and market execution difficulties. Resources from Byte are being redeployed to strengthen the professional SureSmile platform, which continues to show growth in the orthodontist channel. The company has expanded its commercial capabilities by launching a virtual sales team reaching over 21,000 accounts and recruiting 100 inside sales representatives. This digital-first sales approach aims to improve customer engagement while reducing costs. Product innovation has accelerated with eight 510(k) regulatory clearances received in 2024, including launches of the Primescan 2 scanner and MIS LYNX implant system. The company has also invested in clinical education programs, hosting DS World events with over 7,000 participants. Looking forward, DENTSPLY SIRONA is exploring strategic alternatives for Wellspect Healthcare, its urology business, to focus resources on core dental markets. The company continues to invest in high-growth areas like digital aligners and connected dental technologies while streamlining operations in traditional product categories.
XRAY company profile · for informational purposes only — not investment advice.
Track XRAY with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free